Sonova Holding AG
GN Store Nord reups Costco hearing aid deal
Jury hits Advanced Bionics with $7M judgment over recalled HiRes 90k cochlear implant
A federal jury awarded a Kentucky couple more than $7.2 million, including nearly $6.3 million in punitive damages, over the failure of their daughter’s Advanced Bionics’ recalled HiRes 90k cochlear implant.
The jury in the lawsuit, filed in the U.S. District Court for Western Kentucky, found that Advanced Bionics didn’t properly test the implant before it hit the market and never told the FDA that it had switched the manufacturer of a key component to a vendor called AstroSeal.
Advanced Bionics Announces FDA Approval for U.S. Market Re-Entry of the HiRes 90K Cochlear Implant
— Distribution of HiRes 90K Cochlear Implants in the United States Now Under Way —
VALENCIA, Calif., Sept. 13, 2011 /PRNewswire/ — Advanced Bionics (AB), the only U.S.-based manufacturer of cochlear implants and a subsidiary of Switzerland-based Sonova, announced today the approval of the FDA for immediate market re-entry of the HiRes 90K cochlear implant in the United States. In recent months, Advanced Bionics received approval from several other regulatory agencies, including Health Canada and the European Notified Body, TUV, to resume distribution of the HiRes 90K implant to Canada and countries accepting the CE Mark.
NxStage Medical adds Yale professor to scientific advisory board | Personnel Moves
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Angeion reports modest progress in second quarter earnings
Angeion Corp.’s (NSDQ:ANGN) FY2011 earnings for its second quarter ending April 30 reported $138,000, or 4 cents per diluted share, in losses, 75.3 percent better than the $559,000 in losses, or 13 cents per diluted share, for the same time last year.
The decreased losses amount to a 69.2 percent difference for the company’s diluted share value.
Sales decreased by less than 1 percent from second quarter FY2010’s $6.9 million to $6.8 million, reported for the second quarter this year.
Medtronic CEO: Company delays naming Bill Hawkins’ successor without comment
What to make of Medtronic (NYSE:MDT) CEO Bill Hawkins’ decision to postpone his retirement?
A spokesman for the Fridley, Minn.-based company declined to answer any questions about the search for a new chief executive.